How do cars work? Early insights from recent clinical studies targeting CD19

OncoImmunology

Volumn 1, Issue 9, 2012, Pages 1577-1583

  Davila, Marco L ^a   Brentjens, Renier ^a   Wang, Xiuyan ^a   Rivière, Isabelle ^a   Sadelain, Michel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adoptive T cell therapy; CD19; Chimeric antigen receptors; Gene therapy

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CD137 ANTIGEN; CD19 ANTIGEN; CD4 ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; LENTIVIRUS VECTOR; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY CD28; MONOCLONAL ANTIBODY CD3; PENTOSTATIN; RETROVIRUS VECTOR;

ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); DRUG TARGETING; EPSTEIN BARR VIRUS; HUMAN; LENTIVIRINAE; LYMPHOCYTE DEPLETION; LYMPHOCYTOPOIESIS; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM;

EID: 84877666359     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22524     Document Type: Review

References (44)

1. Sadelain M, Rivière I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003; 3:35-45; PMID:12509765; http://dx.doi.org/10.1038/nrc971.
2. Ho WY, Blattman JN, Dossett ML, Yee C, Greenberg PD. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 2003; 3:431-7; PMID:12781360; http://dx.doi.org/10.1016/S1535-6108(03)00113-2.
3. Brenner MK, Heslop HE. Adoptive T cell therapy of cancer. Curr Opin Immunol 2010; 22:251-7; PMID:20171074; http://dx.doi.org/10.1016/j.coi.2010.01.020.
4. Sadelain M, Brentjens R, Rivière I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009; 21:215-23; PMID:19327974; http://dx.doi.org/10.1016/j.coi.2009.02.009.
5. Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol 2002; 20:70-5; PMID:11753365; http://dx.doi.org/10.1038/nbt0102-70.
6. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010; 116:4099-102; PMID:20668228; http://dx.doi.org/10.1182/blood-2010-04-281931.
7. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3:95ra73; PMID:21832238; http://dx.doi.org/10.1126/scitranslmed.3002842.
8. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725- 33; PMID:21830940; http://dx.doi.org/10.1056/NEJMoa1103849.
9. Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011; 118:4817-28; PMID:21849486; http://dx.doi.org/10.1182/blood-2011-04-348540.
10. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokineassociated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2011; 119:2709-20; PMID:22160384.
11. Li YS, Wasserman R, Hayakawa K, Hardy RR. Identification of the earliest B lineage stage in mouse bone marrow. Immunity 1996; 5:527-35; PMID:8986713; http://dx.doi.org/10.1016/S1074-7613(00)80268-X.
12. Li YS, Hayakawa K, Hardy RR. The regulated expression of B lineage associated genes during B cell differentiation in bone marrow and fetal liver. J Exp Med 1993; 178:951-60; PMID:8350062; http://dx.doi.org/10.1084/jem.178.3.951.
13. Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 2003; 9:279-86; PMID:12579196; http://dx.doi.org/10.1038/nm827.
14. Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 2007; 13:5426-35; PMID:17855649; http://dx.doi.org/10.1158/1078-0432.CCR-07-0674.
15. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009; 17:1453-64; PMID:19384291; http://dx.doi.org/10.1038/mt.2009.83.
16. Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 2006; 66:10995-1004; PMID:17108138; http://dx.doi.org/10.1158/0008-5472.CAN-06-0160.
17. Cooper LJ, Topp MS, Serrano LM, Gonzalez S, Chang WC, Naranjo A, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 2003; 101:1637-44; PMID:12393484; http://dx.doi.org/10.1182/blood-2002-07-1989.
18. Kohn DB, Dotti G, Brentjens R, Savoldo B, Jensen M, Cooper LJ, et al. CARs on track in the clinic. Mol Ther 2011; 19:432-8; PMID:21358705; http://dx.doi.org/10.1038/mt.2011.1.
19. Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 2010; 16:1245-56; PMID:20304086; http://dx.doi.org/10.1016/j.bbmt.2010.03.014.
20. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptormodified T cells in lymphoma patients. J Clin Invest 2011; 121:1822-6; PMID:21540550; http://dx.doi.org/10.1172/JCI46110.
21. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin- T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A 1989; 86:10024-8; PMID:2513569; http://dx.doi.org/10.1073/pnas.86.24.10024.
22. Romeo C, Seed B. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell 1991; 64:1037-46; PMID:1900456; http://dx.doi.org/10.1016/0092-8674(91)90327-U.
23. Brocker T, Karjalainen K. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J Exp Med 1995; 181:1653- 9; PMID:7722445; http://dx.doi.org/10.1084/jem.181.5.1653.
24. Gong MC, Latouche JB, Krause A, Heston WD, Bander NH, Sadelain M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1999; 1:123-7; PMID:10933046; http://dx.doi.org/10.1038/sj.neo.7900018.
25. Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl- XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther 2010; 18:413-20; PMID:19773745; http://dx.doi.org/10.1038/mt.2009.210.
26. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 2009; 106:3360- 5; PMID:19211796; http://dx.doi.org/10.1073/pnas.0813101106.
27. Song DG, Ye Q, Poussin M, Harms GM, Figini M, Powell DJ Jr. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood 2012; 119:696-706; PMID:22117050; http://dx.doi.org/10.1182/blood-2011-03-344275.
28. Tammana S, Huang X, Wong M, Milone MC, Ma L, Levine BL, et al. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum Gene Ther 2010; 21:75-86; PMID:19719389; http://dx.doi.org/10.1089/hum.2009.122.
29. Pulè MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 2005; 12:933-41; PMID:15979412; http://dx.doi.org/10.1016/j.ymthe.2005.04.016.
30. Stephan MT, Ponomarev V, Brentjens RJ, Chang AH, Dobrenkov KV, Heller G, et al. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med 2007; 13:1440-9; PMID:18026115; http://dx.doi.org/10.1038/nm1676.
31. Wang J, Jensen M, Lin Y, Sui X, Chen E, Lindgren CG, et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther 2007; 18:712-25; PMID:17685852; http://dx.doi.org/10.1089/hum.2007.028.
32. Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X, et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol 2009; 183:5563-74; PMID:19843940; http://dx.doi.org/10.4049/jimmunol.0900447.
33. Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL, et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004; 18:676-84; PMID:14961035; http://dx.doi.org/10.1038/sj.leu.2403302.
34. Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012; 119:3940-50; PMID:22308288; http://dx.doi.org/10.1182/blood-2011-10-387969.
35. Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 2012; 4:132ra53; PMID:22553251; http://dx.doi.org/10.1126/scitranslmed.3003761.
36. Burns WR, Zheng Z, Rosenberg SA, Morgan RA. Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation. Blood 2009; 114:2888-99; PMID:19589923; http://dx.doi.org/10.1182/blood-2009-01-199216.
37. Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 2012; 119:4133-41; PMID:22354001; http://dx.doi.org/10.1182/blood-2011-12-400044.
38. Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 2010; 116:3875-86; PMID:20631379; http://dx.doi.org/10.1182/blood-2010-01-265041.
39. Cheadle EJ, Hawkins RE, Batha H, O'Neill AL, Dovedi SJ, Gilham DE. Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells. J Immunol 2010; 184:1885-96; PMID:20089697; http://dx.doi.org/10.4049/jimmunol.0901440.
40. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26:5233-9; PMID:18809613; http://dx.doi.org/10.1200/JCO.2008.16.5449.
41. Lamanna N, Kalaycio M, Maslak P, Jurcic JG, Heaney M, Brentjens R, et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006; 24:1575- 81; PMID:16520464; http://dx.doi.org/10.1200/JCO.2005.04.3836.
42. Iannitto E, Morabito F, Mancuso S, Gentile M, Montanini A, Augello A, et al. Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study. Br J Haematol 2011; 153:351-7; PMID:21371003; http://dx.doi.org/10.1111/j.1365-2141.2011.08597.x.
43. Delgado J, Espinet B, Oliveira AC, Abrisqueta P, de la Serna J, Collado R, et al.; on behalf of the Grupo Español de Leucemia Linfatica Cronica (GELLC) y Grupo Español de Citogenetica Hematologica (GECGH). Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results. Br J Haematol 2012; In Press; PMID:22224845; http://dx.doi.org/10.1111/j.1365-2141.2011.09000.x.
44. Zola H, MacArdle PJ, Bradford T, Weedon H, Yasui H, Kurosawa Y. Preparation and characterization of a chimeric CD19 monoclonal antibody. Immunol Cell Biol 1991; 69:411-22; PMID:1725979; http://dx.doi.org/10.1038/icb.1991.58.